Literature DB >> 21547506

A comparison on insulin regimen treatment of elderly (>70 years) and younger (<70 years) type 2 diabetic patients in actual clinical practice.

Carles Zafon1, Carmen Creus.   

Abstract

The incidence of type 2 diabetes mellitus increases with age. However, there are few data about the most adequate type of insulin, or the most adequate insulin regimen, for elderly patients with diabetes. The present study compared insulin regimens in patients aged more than 70 years (100 subjects) with those aged less than 70 years (73 subjects) who attended a diabetes outpatient clinic. The weight, body mass index, diabetes-associated chronic complications, other cardiovascular risk factors, type of insulin, insulin regimen, total daily dose of insulin, weight-adjusted total daily dose of insulin, concomitant treatment with oral hypoglycaemic agents (OHA) and glycosylated haemoglobin (HbA1c) were compared between the two groups. Although both groups had the same level of metabolic control (HbA1c: 7.66 ± 0.91 in the elderly group vs. 7.62 ± 0.96 in the younger group), we have found that elderly subjects were more likely to be treated with a simple regimen, as shown by a higher use of basal insulin (15% in young patients and 41% in the elderly group; P < 0.001), lower use of fast-acting insulin (32.8% vs. 15%; P = 0.005), and fewer daily injections (45% vs. 22% received at least three injections each day; P = 0.001). There were no differences in the use of OHA; however, the majority of young patients were treated with metformin, whereas repaglinide was most commonly used in the elderly group. In conclusion, in everyday clinical practice, elderly subjects were treated with the simplest regimen and achieved the same level of metabolic control as young diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547506     DOI: 10.1007/s00592-011-0289-6

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  4 in total

1.  Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials.

Authors:  Bradley H Curtis; Tina M Rees; Kim A Gaskins; Justo Sierra-Johnson; Rong Liu; Honghua H Jiang; John H Holcombe
Journal:  Aging Clin Exp Res       Date:  2014-02       Impact factor: 3.636

Review 2.  Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?

Authors:  Supriya Mathur; Nicola N Zammitt; Brian M Frier
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

3.  Management of type 2 diabetes mellitus in older patients: current and emerging treatment options.

Authors:  Etie Moghissi
Journal:  Diabetes Ther       Date:  2013-10-05       Impact factor: 2.945

4.  Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.

Authors:  Juraj Secnik; Hong Xu; Emilia Schwertner; Niklas Hammar; Michael Alvarsson; Bengt Winblad; Maria Eriksdotter; Sara Garcia-Ptacek; Dorota Religa
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.